文献速递妇科肿瘤

探索并比较PARP抑制剂之间的不良事件

Exploring and comparing adverse events between PARP inhibitors.
PubMed 文献 · Lancet Oncol · 2019-01-01

本文综述了聚(ADP-核糖)聚合酶(PARP)抑制剂在卵巢癌治疗中的毒性特征,涵盖单药及与其他药物新型联合方案,重点比较三种已获美国食品药品监督管理局(FDA)批准的PARP抑制剂各自的不良事件谱,并探讨减轻毒性反应的管理策略。

要点

  • PARP抑制剂并非完全无害,整体呈现类效应不良事件谱。
  • 自2014年以来已有三种PARP抑制剂获美国食品药品监督管理局批准,各有特定适应症和个体化毒性谱。
  • 全面了解所有相关毒性对确保患者获得最大临床获益至关重要。

核心结论

  • 尽管PARP抑制剂因靶向作用机制看似毒性较低,但并非完全良性,整体呈现类效应不良事件谱。
  • 全面理解所有相关毒性对于确保患者获得最大临床获益至关重要。

研究设计与样本

  • 本文为综述,系统描述并比较每种PARP抑制剂在单药及与其他药物新型联合方案中的所有毒性。

主要发现

  • PARP抑制剂在具有BRCA1或BRCA2突变或同源重组修复通路功能缺陷的卵巢癌患者中显现疗效。
  • 自2014年以来美国食品药品监督管理局已批准三种不同的PARP抑制剂,各有特定适应症和个体化毒性谱。
  • 该类药物的不良事件在类药物内部及不同药物之间均呈现多样性。

关键数值与推荐

  • 自2014年以来,美国食品药品监督管理局已批准三种PARP抑制剂。

临床怎么用

  • 本文重点讨论潜在管理策略以帮助减轻毒性反应,为临床决策提供综合参考。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Ovarian cancer remains one of the most challenging malignancies to treat. Targeted therapies such as poly (ADP-ribose) polymerase (PARP) inhibitors have emerged as one of the most exciting new treatments for ovarian cancer, particularly in women with BRCA1 or BRCA2 mutations or those without a functional homologous recombination repair pathway. Perhaps the most advantageous characteristic of PARP inhibitors is their mechanism of action, which targets cancer cells on the basis of their inherent deficiencies while seemingly avoiding normally functioning cells. Although health-care providers might assume a low toxicity profile because of their specific mechanism of action, PARP inhibitors are not completely benign and overall show a class effect adverse-event profile. Further complicating this situation, three different PARP inhibitors have been approved by the US Food and Drug Administration since 2014, each with their own specific indications and individual toxicity profiles. The diversity of adverse events seen both within and across this class of drug underscores the importance of having a comprehensive reference to help guide clinical decision making when treating patients. This Review characterises and compares all toxicities associated with each PARP inhibitor, both in monotherapy and in novel combinations with other drugs, with a particular focus on potential management strategies to help mitigate toxic effects. Although the excitement surrounding PARP inhibitors might certainly be warranted, a thorough understanding of all associated toxicities is imperative to ensure that patients can achieve maximal clinical benefit.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. LaFargue CJ, Dal Molin GZ, Sood AK, et al. Exploring and comparing adverse events between PARP inhibitors. Lancet Oncol. 2019. PMID: 30614472. doi:10.1016/S1470-2045(18)30786-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。